{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:21:39Z","timestamp":1789507299579,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory syndrome. HLH can occur as a primary (familial) or secondary (acquired) disorder. Secondary HLH (sHLH) manifests in response to infection, malignancy, autoimmune disorders or drugs. Presentation is usually non-specific, with fever, cytopenias, elevated inflammatory markers and hepatosplenomegaly. A high level of suspicion coupled with the use of diagnostic scores (HScore and HLH-2004) is required for timely diagnosis. Specific studies such as bone marrow biopsy or soluble interleukin-2 (IL-2) receptor (CD25) levels are necessary for distinguishing HLH from other conditions, but should not delay treatment. Corticosteroids, in addition to other immunossupressants, should be initiated promptly in order to reduce morbidity and mortality. In secondary cases, treatment of underlying causes is necessary for complete remission. Long-term immunossupression may be required beyond resolution of the HLH trigger to avoid relapses. We report a case of severe acute HLH in a patient with distributive and cardiogenic shock and multiorgan dysfunction. The patient was successfully treated with CytoSorb\n                    <jats:sup>\u00ae<\/jats:sup>\n                    hemoadsorption therapy. This case highlights diagnostic challenges, therapeutic interventions, and the potential role of hemoadsorption therapy as a complementary treatment option for HLH.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2025.1729061","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:18Z","timestamp":1766040198000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A role for hemoadsorption in hemophagocytic lymphohistiocytosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Miguel Gon\u00e7alves","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Burgi","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Isidoro","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Germano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1046\/j.1365-2141.2001.02936.x","article-title":"Pathogenesis of haemophagocytic lymphohistiocytosis","volume":"114","author":"Aric\u00f3","year":"2001","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How i treat hemophagocytic lymphohistio- cytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cytogfr.2014.10.001","article-title":"Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders","volume":"26","author":"Brisse","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"ref6","volume-title":"CytoSorbents, CytoSorb\u00ae \u2014 The Adsorber [Internet]","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00432-020-03139-4","article-title":"Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry","volume":"146","author":"Birndt","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-023-04323-x","article-title":"Cytokine hemoadsorption with CytoSorb\u00ae in post-cardiac arrest syndrome, a pilot randomized controlled trial","volume":"27","author":"Monard","year":"2023","journal-title":"Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12882-020-02020-3","article-title":"Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)","volume":"21","author":"Asgharpour","year":"2020","journal-title":"BMC Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"779038","DOI":"10.3389\/fmed.2021.779038","article-title":"Cytokine hemoadsorption as rescue therapy for critically ill patients with SARS-CoV-2 pneumonia with severe respiratory failure and hypercytokinemia","volume":"8","author":"Monard","year":"2021","journal-title":"Front Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/s-0040-1708479","article-title":"Combined use of CytoSorb and ECMO in patients with severe pneumogenic sepsis","volume":"69","author":"Akil","year":"2020","journal-title":"Thorac Cardiovasc Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13054-019-2588-1","article-title":"Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study","volume":"23","author":"Brouwer","year":"2019","journal-title":"Crit Care"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcrc.2018.11.003","article-title":"Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study","volume":"49","author":"Hawchar","year":"2019","journal-title":"J Crit Care"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-019-2399-4","article-title":"Cytokine clearance with CytoSorb\u00ae during cardiac surgery: a pilot randomized controlled trial","volume":"23","author":"Poli","year":"2019","journal-title":"Crit Care"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/0391398819857444","article-title":"Cytokine adsorption is a promising tool in the therapy of hemophagocytic lymphohistiocytosis","volume":"42","author":"Frimmel","year":"2019","journal-title":"Int J Artif Organs"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10875-017-0377-7","article-title":"Rescue of cytokine storm due to HLH by hemoadsorption in a CTLA4-deficient pa- tient","volume":"37","author":"Greil","year":"2017","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1729061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:24Z","timestamp":1766040204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1729061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":17,"alternative-id":["10.3389\/fmed.2025.1729061"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1729061","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1729061"}}